{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": 6.46, "sharesOutstanding": 1560540032, "bookValue": 1986.4525, "fiftyDayAverage": 83.5134, "fiftyDayAverageChange": 0.35660553, "fiftyDayAverageChangePercent": 0.00427004, "twoHundredDayAverage": 76.99215, "twoHundredDayAverageChange": 6.8778534, "twoHundredDayAverageChangePercent": 0.08933188, "marketCap": 262616268800, "priceToBook": 0.042220995, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "currency": "BRL", "financialCurrency": "JPY", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 9, "averageDailyVolume10Day": 23, "fiftyTwoWeekLowChange": 83.87, "fiftyTwoWeekRange": "0.0 - 86.5", "fiftyTwoWeekHighChange": -2.6299973, "fiftyTwoWeekHighChangePercent": -0.030404592, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 86.5, "trailingAnnualDividendRate": 180.0, "trailingPE": 12.982972, "trailingAnnualDividendYield": 2.1461785, "firstTradeDateMilliseconds": 1576587600000, "priceHint": 2, "marketState": "PREPRE", "regularMarketChange": 0.0, "regularMarketTime": 1683728933, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 0, "regularMarketPreviousClose": 83.87, "bid": 79.81, "ask": 88.24, "fullExchangeName": "S\u00e3o Paulo", "regularMarketChangePercent": 0.0, "regularMarketPrice": 83.87, "exchangeTimezoneName": "America/Sao_Paulo", "exchangeTimezoneShortName": "BRT", "gmtOffSetMilliseconds": -10800000, "esgPopulated": false, "exchange": "SAO", "shortName": "TAKEDAPH    DRN", "longName": "Takeda Pharmaceutical Company Limited", "messageBoardId": "finmb_874540", "market": "br_market", "symbol": "TAKP34.SA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1-1, Nihonbashi-Honcho 2-chome", "address2": "Chuo-ku", "city": "Tokyo", "zip": "103-8668", "country": "Japan", "phone": "81 3 3278 2111", "fax": "81 3 3278 2000", "website": "https://www.takeda.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.", "fullTimeEmployees": 47347, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christophe  Weber", "age": 56, "title": "Pres, CEO & Representative Director", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 4389660, "fmt": "4.39M", "longFmt": "4,389,660"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Constantine  Saroukos", "age": 51, "title": "CFO & Representative Director", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 2623450, "fmt": "2.62M", "longFmt": "2,623,450"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Andrew S.  Plump", "age": 57, "title": "Pres of R&D and Representative Director", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 2490430, "fmt": "2.49M", "longFmt": "2,490,430"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Seigo  Izumo", "title": "Chair of Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Haruhiko  Hirate", "age": 65, "title": "Member of Management Board", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Salvatore  Alesci", "title": "Member of Management Board and Head of R&D Global Science & Biomedical Policy", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Norimasa  Takeda", "title": "Chief Accounting Officer & Corp. Controller", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Iwaaki  Taniguchi", "title": "Sr. VP of Corp. Fin. & Controlling Department", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Gabriele  Ricci", "age": 44, "title": "Chief Data & Technology Officer", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher David  O'Reilly", "title": "Global Head of Investor Relations & Global Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 1, "boardRisk": 1, "compensationRisk": 1, "shareHolderRightsRisk": 8, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}